R. V. van Heeswijk

发表

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.

J. Beijnen, A. Hsu, J. Lange, 1999, AIDS.

Review of Drug Interactions with Telaprevir and Antiretrovirals

V. Garg, M. Beumont, R. V. van Heeswijk, 2013, Antiviral therapy.

Effect of Telaprevir on the Pharmacokinetics of Buprenorphine in Volunteers on Stable Buprenorphine/Naloxone Maintenance Therapy

V. Garg, J. Trevejo, R. V. van Heeswijk, 2012, Antimicrobial Agents and Chemotherapy.

Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.

R. Hoetelmans, R. V. van Heeswijk, R. Heeswijk, 2014, The Journal of antimicrobial chemotherapy.

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

V. Garg, Katia Alves, R. V. van Heeswijk, 2011, Hepatology.

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

P. Reiss, J. Beijnen, F. Wit, 2000, AIDS.

Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.

H. Crauwels, R. Hoetelmans, R. V. van Heeswijk, 2013, AIDS reviews.

Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.

H. Crauwels, R. Hoetelmans, R. V. van Heeswijk, 2014, International journal of clinical pharmacology and therapeutics.

The effect of rilpivirine on the pharmacokinetics of methadone in HIV‐negative volunteers

H. Crauwels, R. Hoetelmans, R. V. van Heeswijk, 2014, Journal of clinical pharmacology.

Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis

A. Diacon, R. Kerstens, R. Rustomjee, 2008, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis Drug

S. Mcleay, B. Green, P. Vis, 2014, Antimicrobial Agents and Chemotherapy.

Saliva as an Alternative Body Fluid for Therapeutic Drug Monitoring of the Nonnucleoside Reverse Transcription Inhibitor Nevirapine

J. Beijnen, J. Lange, J. Mulder, 2001, Therapeutic drug monitoring.

Pharmacokinetic Interaction between Telaprevir and Methadone

V. Garg, J. Snoeys, P. Verboven, 2013, Antimicrobial Agents and Chemotherapy.

Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.

G. Kroemer, S. Bennett, G. Bren, 2005, The Journal of clinical investigation.

Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.

G. Garber, D. Cameron, R. V. van Heeswijk, 2005, British journal of clinical pharmacology.

Steady‐State Pharmacokinetics of Twice‐Daily Dosing of Saquinavir Plus Ritonavir in HIV‐1‐Infected Individuals

J. Beijnen, J. Lange, J. Mulder, 2001, Journal of Acquired Immune Deficiency Syndromes.

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.

J. Aerssens, S. Zeuzem, S. Pol, 2013, Journal of hepatology.

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.

O. Weiland, G. Foster, G. Carosi, 2011, Gastroenterology.

Prevention of Drug Carryover Effects in Studies Assessing Antimycobacterial Efficacy of TMC207

K. Andries, N. Lounis, T. Verhaeghe, 2008, Journal of Clinical Microbiology.

Once‐daily nevirapine dosing: a pharmacokinetics, efficacy and safety review

C. Cooper, R. V. van Heeswijk, C. Cooper, 2007, HIV medicine.

Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma – drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study

J. Beijnen, J. Mulder, R. Hoetelmans, 1999, Cancer Chemotherapy and Pharmacology.

Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.

S. Jurriaans, J. Prins, J. Lange, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV‐1 infected individuals

P. Reiss, J. Beijnen, J. Lange, 1998, AIDS.

Evaluation of HIV Drug Interaction Web Sites

C. Hughes, N. Sheehan, A. Tseng, 2003, The Annals of pharmacotherapy.

Co-trimoxazole and stavudine interference in a high-performance liquid chromatographic analysis for didanosine in human plasma.

J. Beijnen, J. Mulder, R. Hoetelmans, 1998, Therapeutic drug monitoring.

Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin

V. Garg, Katia Alves, R. V. van Heeswijk, 2011, Antimicrobial Agents and Chemotherapy.

Telaprevir for retreatment of HCV infection.

O. Weiland, F. Nevens, S. Zeuzem, 2011, The New England journal of medicine.

Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir.

J. Beijnen, J. V. D. van der Meer, J. Mulder, 2000, AIDS.

Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

K. Andries, A. H. Diacon, A. Diacon, 2012, Antimicrobial Agents and Chemotherapy.

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis

A. Diacon, K. Andries, N. Lounis, 2015, European Respiratory Journal.

Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine

H. Crauwels, R. Hoetelmans, R. V. van Heeswijk, 2013, Journal of clinical pharmacology.

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

P. Marcellin, X. Forns, F. Nevens, 2011, Gastroenterology.

The Pharmacokinetics of Nelfinavir in HIV-1—Infected Children

J. Beijnen, H. Heymans, Linda A de Koning, 2002, Therapeutic drug monitoring.

Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.

K. Ruxrungtham, D. Cooper, P. Phanuphak, 2003, Journal of acquired immune deficiency syndromes.

Critical Issues in Therapeutic Drug Monitoring of Antiretroviral Drugs

R. V. van Heeswijk, 2002, Therapeutic drug monitoring.

Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.

J. Beijnen, J. Lange, J. Mulder, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Stable Concentrations of Zidovudine, Stavudine, Lamivudine, Abacavir, and Nevirapine in Serum and Cerebrospinal Fluid during 2 Years of Therapy

S. Jurriaans, J. Prins, J. Sommadossi, 2002, Antimicrobial Agents and Chemotherapy.

Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection.

J. Beijnen, J. Mulder, R. Hoetelmans, 1998, Journal of chromatography. B, Biomedical sciences and applications.

A review of low-dose ritonavir in protease inhibitor combination therapy.

C. Cooper, K. Gallicano, D. Cameron, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection.

J. Beijnen, J. Lange, J. Mulder, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children

C. Rongkavilit, R. V. van Heeswijk, C. Mitchell, 2008, Antiviral therapy.

Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection.

J. Beijnen, J. Lange, J. Mulder, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Simplifying Protease Inhibitor Therapy with Once‐Daily Dosing of Saquinavir Soft‐Gelatin Capsules/Ritonavir (1600/100 mg): HIVNAT 001.3 Study

K. Ruxrungtham, D. Cooper, J. Beijnen, 2002, Journal of acquired immune deficiency syndromes.

Pharmacokinetics of Indinavir/Ritonavir (800/100 mg) in Combination With Efavirenz (600 mg) in HIV‐1‐Infected Subjects

K. Ruxrungtham, D. Cooper, P. Phanuphak, 2003, Journal of acquired immune deficiency syndromes.

The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Gavin Churchyard, Alexander Pym, Paul Meyvisch, 2009, The New England journal of medicine.

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

Eduardo Gotuzzo, Alexander Pym, Paul Meyvisch, 2014, The New England journal of medicine.

Telaprevir: Pharmacokinetics and Drug Interactions

V. Garg, R. V. van Heeswijk, R. Kauffman, 2012, Antiviral therapy.

The Effect of β-Carotene Supplementation on the Pharmacokinetics of Nelfinavir and Its Active Metabolite M8 in HIV-1-infected Patients

Neeraj Singhal, N. Sheehan, R. Lalonde, 2012, Molecules.

Dose‐Escalating Study of the Safety and Pharmacokinetics of Nelfinavir in HIV‐Exposed Neonates

K. Ruxrungtham, D. Cooper, P. Phanuphak, 2002, Journal of acquired immune deficiency syndromes.

Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men

D. Pillay, S. Taylor, J. Workman, 2000, AIDS.

Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers

C. Flexner, E. Fuchs, M. Elgadi, 2009, Antimicrobial Agents and Chemotherapy.

Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells.

O. Janneh, R. V. van Heeswijk, K. Copeland, 2010, Drug metabolism letters.

Steady-State Pharmacokinetics and Tolerability of Indinavir-Lopinavir/R Combination Therapy in Antiretroviral-Experienced Patients

T. Antoniou, E. Phillips, S. Walker, 2005, Therapeutic Drug Monitoring.

Limited Sampling Strategies for the Estimation of the Systemic Exposure to the HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Nevirapine

J. Beijnen, J. Mulder, R. Hoetelmans, 2001, Therapeutic drug monitoring.

Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers: AIDS Clinical Trials Group Study A5267

K. Dooley, J. Park, C. Flexner, 2012, Journal of acquired immune deficiency syndromes.

Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy

A. Rieger, M. de Béthune, A. Pozniak, 2008, Antiviral therapy.